Abstract
Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25% to 10%. Results. Three (38%) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13%). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25%) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.
| Original language | English |
|---|---|
| Journal | Oncologist |
| Volume | 22 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
A phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer. / Lolli, Cristian; Gallà, Valentina; Schepisi, Giuseppe; Barone, Domenico; Burgio, Salvatore Luca; Maugeri, Antonio; Vertogen, Bernadette; Amadori, Dino; de Giorgi, Ugo.
In: Oncologist, Vol. 22, No. 7, 01.07.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer
AU - Lolli, Cristian
AU - Gallà, Valentina
AU - Schepisi, Giuseppe
AU - Barone, Domenico
AU - Burgio, Salvatore Luca
AU - Maugeri, Antonio
AU - Vertogen, Bernadette
AU - Amadori, Dino
AU - de Giorgi, Ugo
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25% to 10%. Results. Three (38%) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13%). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25%) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.
AB - Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25% to 10%. Results. Three (38%) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13%). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25%) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.
UR - http://www.scopus.com/inward/record.url?scp=85024111426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024111426&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2017-0154
DO - 10.1634/theoncologist.2017-0154
M3 - Article
AN - SCOPUS:85024111426
VL - 22
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 7
ER -